Haemonetics Corp (NYSE: HAE) has reported earnings for its fourth fiscal quarter (ending March 31) of $0.40 versus $0.58 for the same period a year ago — a decline of -31%. This result fell short of the consensus estimate of $0.89 by $-0.49. For the latest four quarters through March 31, E.P.S. were $2.32 versus $2.27 for the same period a year ago — an increase of 2%.
Recent Price Action
Haemonetics Corp (NYSE: HAE) stock declined slightly by -0.7% on 5/9/24. The stock closed at $92.60. Moreover, unusually high trading volume at 189% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 0.5% during the last week.
Current PriceTarget Research Rating
HAE’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Haemonetics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Haemonetics has a slightly negative Power Rating of 31 and a poor Appreciation Score of 16, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment